PLX

AI Memo

Protalix Biotherapeutics

As of 2026-09-07/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

PRX-115 Phase 2 enrollment progress • 2026-12-31

Base target: $3 / p=55% prob

Biggest risk

Revenue may remain lumpy because of partner shipments and inventory timing. PRX-115 remains a development-stage, binary program with results not expected until the second half of 2027, while rising R&D investment and limited coverage increase uncertainty.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Elfabrio growth, reaffirmed 2026 guidance, cash of $40.7 million, and continued PRX-115 enrollment provide a constructive operating setup. The long-term upside depends on commercial penetration and successful clinical execution.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-07

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Elfabrio commercial execution and 2026 guidance
PRX-115 Phase 2 top-line readout
Elfabrio growth, reaffirmed 2026 guidance, cash of $40.7 million, and continued PRX-115 enrollment provide a constructive operating setup.

BearKey bullets

Analyst revisions, options data, short interest, social sentiment, employee sentiment, and verified post-release price reaction are unavailable.
PRX-115 clinical enrollment, safety, efficacy, and timing remain execution risks.
Partner shipment timing and inventory cycles may make quarterly revenue volatile.

WatchKey bullets

PRX-115 Phase 2 enrollment progress

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $3 (p=55%)

Target spread vs base: +41% / -47%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $3 (p=55%)Bear Target: $2 (p=25%)

Commentary

Recent coverage is constructive around Q2 results, Elfabrio growth, reaffirmed guidance, and PRX-115 progress. However, PLX is low coverage, social coverage is absent, and analyst revision and market-reaction data are unavailable. The evidence supports a monitoring-oriented speculative thesis rather than a high-conviction rerating call.

As of 2026-09-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Elfabrio commercial execution and 2026 guidance
PRX-115 Phase 2 top-line readout

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$3 / p=55% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-09-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
PRX-115 Phase 2 enrollment progress
The RELEASE Phase 2 study continues enrollment, with stored earnings-call context indicating management expects enrollment completion by year-end 2026 [#PR-EARNINGS-2026-08-14].
Prob 60.00% • Move 15.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Elfabrio commercial execution and 2026 guidance
2026-12-31
Q2 revenue from selling goods reached $19.8 million, total first-half revenue reached $53.6 million including the Chiesi milestone, and management reiterated full-year 2026 revenue guidance of $78-$83 million [#SEC-8K-2026-08-12].
Prob 65% • Move 10% • Priced-in 55%

Long-term Catalysts

Months to a year

PRX-115 Phase 2 top-line readout
2027-09-07
The company anticipates top-line results from the RELEASE Phase 2 trial in the second half of 2027, creating a potentially material but binary clinical catalyst [#SEC-8K-2026-08-12].
Prob 45% • Move 35% • Priced-in 20%

Risks

Analyst revisions, options data, short interest, social sentiment, employee sentiment, and verified post-release price reaction are unavailable.
PRX-115 clinical enrollment, safety, efficacy, and timing remain execution risks.
Partner shipment timing and inventory cycles may make quarterly revenue volatile.
R&D spending is expected to rise as the RELEASE study and additional pipeline programs advance.
Top-line clinical results are not expected until the second half of 2027, leaving limited near-term visibility.

Peers

Symbol	Summary
ABOS	Similar-market-cap biotechnology comparator; direct product or indication overlap with PLX is not established.
CHRS	Same-sector, similar-size biotech comparator; useful mainly for small-cap biotech risk appetite.
CUE	Small-cap biotechnology comparator with limited demonstrated comparability to PLX's Fabry and gout programs.
DERM	Same-sector, similar-market-cap biotech comparator; direct commercial or clinical overlap is not established.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-07

Loading AI feed…

Symbol

Summary

ABOS

Similar-market-cap biotechnology comparator; direct product or indication overlap with PLX is not established.

CHRS

Same-sector, similar-size biotech comparator; useful mainly for small-cap biotech risk appetite.

CUE

Small-cap biotechnology comparator with limited demonstrated comparability to PLX's Fabry and gout programs.

DERM

Same-sector, similar-market-cap biotech comparator; direct commercial or clinical overlap is not established.